CAR T-cell Therapy | Specialty

Tisagenlecleucel for Pediatric and Young Adult ALL

January 8th 2019

Potential Use of CAR T-Cell Therapy Earlier in Sequencing

January 8th 2019

Optimizing the Use of CAR T-Cell Therapy in Lymphoma

January 8th 2019

CAR T-Cell Therapy: Real-World Applications

January 8th 2019

A Historic Perspective on High-Risk Lymphoma Management

January 8th 2019

Clinical Trial Data for Respective CAR T-Cell Therapies

January 8th 2019

Despite Progress With CAR T-Cell Therapy, Transplant Retains Role in Myeloma

January 3rd 2019

Deepu Madduri, MD, discusses the status of transplant for eligible patients and the developments that are being made with CAR T-cell therapy in multiple myeloma.

Lead Researcher Highlights Tisagenlecleucel Benefit in Younger Leukemia Patients

January 3rd 2019

Stephen Grupp, MD, PhD, discusses the updated analysis of the ELIANA trial and its implications for pediatric and young adult patients with relapsed/refractory acute lymphoblastic leukemia.

Dr. Grupp on the Optimal Setting of CAR T-Cell Therapy in ALL

January 2nd 2019

Stephan Grupp, MD, PhD, director, Cancer Immunotherapy Program, director, Translational Research for the Center for Childhood Cancer Research, medical director, Stem Cell Laboratory, Children’s Hospital of Philadelphia, discusses the placement of chimeric antigen receptor (CAR) T-cell therapy in the treatment of patients with acute lymphoblastic leukemia (ALL).

Dr. Ghobadi on Ways of Reducing the Cost of CAR T-Cell Therapy

December 20th 2018

Armin Ghobadi, MD, assistant professor of medicine, Division of Medical Oncology, Washington University School of Medicine, Siteman Cancer Center, discusses ways of reducing the cost of chimeric antigen receptor (CAR) T-cell therapy.

Dr. Gauthier on Potential for CAR T Cells in CLL

December 11th 2018

Jordan Gauthier, MD, MSc, senior clinical research fellow, Fred Hutchinson Cancer Research Center, discusses the potential for chimeric antigen receptor T-cell therapy in the treatment of chronic lymphocytic leukemia.

Dr. Madduri on Treatment After CAR T Cells in Myeloma

December 11th 2018

Deepu Madduri, MD, assistant professor, Mount Sinai Hospital, discusses treatment after CAR T-cell therapy in patients with myeloma.

Dr. Pulsipher on MRD in Pediatric Patients Treated With CAR T Cells

December 7th 2018

Michael Pulsipher, MD, director of cellular therapy and stem cell transplantation, professor of pediatrics, USC Keck School of Medicine, discusses the role of MRD testing in pediatric patients treated with CAR T-cell therapy.

Axi-Cel Efficacy Persists at 2-Year Assessment for Large B-Cell Lymphoma

December 4th 2018

Axicabtagene ciloleucel elicited a 2-year overall survival rate of 51% in patients with refractory large B cell lymphoma, representing a clear plateau in the survival curve.

Liso-Cel Demonstrates Durable Responses in Heavily Pretreated, High-Risk CLL

December 3rd 2018

Lisocabtagene maraleucel appeared tolerable and induced an 81.3% best overall response rate and 43.8% complete response rate in heavily pretreated, high-risk patients with chronic lymphocytic leukemia who previously received ibrutinib.

Checkpoint Inhibition May Improve CAR T-Cell Persistence

December 2nd 2018

Checkpoint inhibition showed promise for augmenting or extending response to chimeric antigen receptor T-cell therapy in some patients with relapsed B-cell acute lymphoblastic leukemia.

Tisagenlecleucel OS, RFS Sustained in Long-Term Follow-Up for Pediatric ALL

December 2nd 2018

Treatment with the CD19-targeted CAR T-cell therapy tisagenlecleucel demonstrated sustained rates of relapse-free survival and overall survival at 24 and 18 months for pediatric and young adult patients with relapsed or refractory acute lymphoblastic leukemia.

Novel T-Cell Therapies Make Inroads Into Solid Tumors

November 28th 2018

Although CAR T-cell therapies have proved successful in certain hematologic malignancies, efforts to employ similar strategies in solid tumors have been challenging. Investigators are working on different forms of adoptive cell therapy in solid tumors and early signs are promising.

Dr. Boccia on Managing Adverse Events With CAR T-Cell Therapy

November 17th 2018

Ralph Boccia, MD, an oncologist at the Center for Cancer and Blood Disorders, associate clinical professor at Georgetown University, discusses managing adverse events associated with chimeric antigen receptor T-cell therapy.

Dr. Goy on Need for Payment Model for CAR T-Cell Therapy

November 17th 2018

Andre Goy, MD, MS, chairman and executive director of the John Theurer Cancer Center at Hackensack University Medical Center, discusses the affordability of cancer treatment breakthroughs such as chimeric antigen receptor T-cell therapy.